Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes Mellitus
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
The purpose of this study is to examine the insulin-sparing effect of sitagliptin 100 mg once-daily compared with placebo over 24 weeks in participants with type 2 diabetes mellitus who have inadequate glycemic control on insulin…
- Trial name
- NCT01462266
- Testing
- Sitagliptin, Insulin Glargine, Metformin
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effects on overall glycaemic control of two insulin intensification therapies.
- Trial name
- NCT01175811
- Testing
- Insulin Lispro Premix, Insulin Glargine, Insulin Lispro
- Where
- 14 sites in China, South Korea and 1 more
- Volunteers
- 402 people
- Sponsor
- Eli Lilly and Company
Diabetes
Phase III Insulin Add-On Asia Regional Program - ST
The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to…
- Trial name
- NCT02096705
- Testing
- Dapagliflozin
- Where
- 29 sites in China, Singapore and 1 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
- Trial name
- NCT00121641
- Testing
- Saxagliptin, Metformin
- Where
- 134 sites in United States, Australia and 4 more
- Volunteers
- 1,035 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
This is a non-inferiority study comparing omarigliptin with sitagliptin in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on metformin therapy.
- Trial name
- NCT01841697
- Testing
- Omarigliptin, Sitagliptin, Open-label Metformin
- Volunteers
- 642 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients
The purpose is to evaluate the proportion of subjects achieving a Hemoglobin A1c (HbA1c) level below 6.5%, when lispro mix 50/50 is introduced in a stepwise manner from every day (QD) administration to type 2 diabetic patients…
- Trial name
- SIMPLE (NCT00971997)
- Testing
- Lispro Mix 50/50
- Where
- 14 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
The purpose of this study is to assess the efficacy and safety of sitagliptin/simvastatin fixed-dose combination (FDC) in participants with T2DM who have inadequate glycemic control while on metformin monotherapy.
- Trial name
- NCT01678820
- Testing
- Sitagliptin/Simvastatin FDC, Sitagliptin, Simvastatin
- Volunteers
- 299 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin.
- Trial name
- NCT01999218
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Glimerpiride
- Volunteers
- 1,326 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone.
- Trial name
- ACHIEVE-1 (NCT05971940)
- Testing
- Orforglipron
- Where
- 89 sites in United States, China and 4 more
- Volunteers
- 559 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.
- Trial name
- NCT00813995
- Testing
- Comparator: Sitagliptin phosphate
- Volunteers
- 395 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
The purpose of the study is to assess the effect of the addition of sitagliptin to metformin with or without a sulfonylurea compared with the addition of dapagliflozin to metformin with or without a sulfonylurea on hemoglobin A1c…
- Trial name
- NCT02532855
- Testing
- Sitagliptin, Dapagliflozin, Metformin
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Non-Insulin-Dependent
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c [HbA1c]…
- Trial name
- NCT00545584
- Testing
- sitagliptin phosphate, Comparator: Diet, Comparator: Physical Activity
- Volunteers
- 1,512 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone
- Trial name
- NCT00327015
- Testing
- Saxagliptin, Metformin, pioglitazone
- Where
- 211 sites in United States, Argentina and 11 more
- Volunteers
- 1,306 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea…
- Trial name
- NCT01106625
- Testing
- Canagliflozin, Metformin, Sulphonylruea
- Where
- 76 sites in United States, Australia and 10 more
- Volunteers
- 469 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled…
- Trial name
- NCT00295633
- Testing
- Saxagliptin, pioglitazone, rosiglitazone
- Where
- 133 sites in United States, Argentina and 6 more
- Volunteers
- 565 people
- Sponsor
- AstraZeneca
Gout
Combining Lesinurad With Allopurinol in Inadequate Responders
This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to…
- Trial name
- CLEAR 1 (NCT01510158)
- Testing
- Lesinurad, Allopurinol
- Where
- 165 sites in United States
- Volunteers
- 607 people
- Sponsor
- Ardea Biosciences, Inc.
Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent
A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)
A study to see if better control of type 2 diabetes can occur in patients taking a stable dose of metformin when they are also provided either sitagliptin or glimepiride.
- Trial name
- NCT00701090
- Testing
- sitagliptin, Comparator: glimepiride, open-label metformin
- Volunteers
- 1,035 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Non-Insulin-Dependent
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
The phase III clinical trial examines the efficacy, safety, and tolerability of the addition of MK0431/ONO-5435 to Japanese patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT00837577
- Testing
- Sitagliptin, Voglibose
- Volunteers
- 133 people
- Sponsor
- Merck Sharp & Dohme LLC
Gout
Combining Lesinurad With Allopurinol in Inadequate Responders
This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to…
- Trial name
- CLEAR 2 (NCT01493531)
- Testing
- Lesinurad, Allopurinol
- Where
- 175 sites in United States, Australia and 9 more
- Volunteers
- 610 people
- Sponsor
- Ardea Biosciences, Inc.